Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children. At the end of 2025, the group had one product in clinical development phase: ADV7103 for the treatment of distal renal tubular acidosis and for the treatment of cystinuria.

Employees

Sector

Pharmaceuticals

Calendar

09-17 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	€0.8660	-1.93%	43,961
10/09/26	€0.8830	-1.89%	69,953
09/09/26	€0.9000	-2.91%	60,476
08/09/26	€0.9270	-0.43%	64,241
07/09/26	€0.9310	-4.02%	58,673

Real-time Euronext Paris

More quotes

Analysis / Opinion

OHB and Soitec ride supportive news flow, Advicenne tumbles

August 31, 2026 at 01:54 pm

More analyses

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 19:55:00 11/09/2026 +04			5-day change	1st Jan Change
0.8660 ^EUR	-1.93%		-10.72%	-49.94%

08-31	Advicenne Decides To Withdraw Its ADV7103 New Drug Application In The USA	CI
08-31	OHB and Soitec ride supportive news flow, Advicenne tumbles

Market Cap	12.6M 14.62M 11.93M 10.81M 20.29M 1.4B 20.39M 142M 54.48M 711M 54.92M 53.71M 2.25B	P/E 2026 *	-1.84x	P/E 2027 *	-1.97x
Enterprise Value	35.7M 41.43M 33.8M 30.64M 57.48M 3.96B 57.77M 401M 154M 2.01B 156M 152M 6.36B	EV / Sales 2026 *	5.41x	EV / Sales 2027 *	5.22x
Free-Float	95.15%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Euronext Paris	ALDVI	Real-time
Börse Stuttgart	3MM	Delayed
Deutsche Boerse AG	3MM	Delayed
Boerse Muenchen	3MM	Real-time
CBOE		Real-time
CBOE		Real-time

08-31	Advicenne Decides To Withdraw Its ADV7103 New Drug Application In The USA	CI
08-31	OHB and Soitec ride supportive news flow, Advicenne tumbles
08-31	Advicenne Withdraws US Application for Distal Renal Tubular Acidosis Drug	MT
07-21	Advicenne's Distal Renal Tubular Acidosis Medicine Secures Reimbursement in Spain	MT
07-16	Advicenne S.A. Reports Sales Results for the First Half of 2026	CI
07-02	UK Regulator Grants 'Unlimited Renewal' of Advicenne's Distal Renal Tubular Acidosis Drug	MT
07-01	Advicenne Announces Unlimited Renewal of Marketing Authorization for Sibnayal in United Kingdom	CI
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne secures its cash runway through the second quarter of 2027
06-23	Advicenne Raises EUR4 Million from Two-tranche Bonds Issuance	MT
06-22	Advicenne S.A. Secures Its Cash Runway to Second Quarter 2027 Through A Bond Financing of A Nominal Amount of Up to EUR 3.8 Million	CI
06-01	Advicenne soars as Likozam secures social security reimbursement
06-01	Advicenne's Likozam added to France's list of reimbursable medicines

Advicenne Stock

Stocks

ALDVI

FR0013296746

Pharmaceuticals

Valuation : Advicenne

Chart: Advicenne

Latest news : Advicenne

Analysts' recommendations : Advicenne

Press Releases : Advicenne

News in other languages : Advicenne

Quotes and Performance

Price Extremes

Managers and Directors : Advicenne

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysis / Opinion

Annual profits - Rate of surprise

08-31	Advicenne decides to withdraw its ADV7103 New Drug Application in the USA	BU
07-20	Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain	BU
07-16	Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France	BU
07-01	Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom	BU
06-23	Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million	AQ

09-12	Agenda des résultats de la semaine : Bolloré, Virbac, Robertet et d'autres valeurs moyennes au programme
09-02	Advicenne poursuit sa correction boursière, la stratégie ne rassure pas
08-31	Coup dur pour Advicenne, qui retire une demande d'approbation aux USA
08-31	OHB et Soitec profitent d'une actualité porteuse, Advicenne sombre
08-31	Paris revient vers l'équilibre après un début de séance en hausse

1 day	-1.93%
1 week	-10.72%
Current month	-20.40%
1 month	-48.88%
3 months	-21.98%
6 months	-53.94%
Current year	-49.94%

1 week	0.85	0.96
1 month	0.84	1.9
Current year	0.8	2.35
1 year	0.8	2.35
3 years	0.8	3.08
5 years	0.8	10.5
10 years	0.8	16.25

Manager	Title	Age	Since
Didier Laurens CEO	Chief Executive Officer	59	03/05/2021
Delphine Dumas CTO	Chief Tech/Sci/R&D Officer	-	01/09/2025
Véronique Leblanc CTO	Chief Tech/Sci/R&D Officer	-	01/04/2023

Director	Title	Age	Since
André Ulmann BRD	Director/Board Member	-	23/06/2017
Catherine Dunand BRD	Director/Board Member	64	09/03/2017
Charlotte Sibley BRD	Director/Board Member	78	20/09/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/12/20	Nathalie Lemarié	Sell	General Counsel	998	0.0123%
29/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%
25/12/20	Nathalie Lemarié	Sell	General Counsel	1,000	0.0124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ADVICENNE	-1.93%	-10.72%	-33.18%	-64.51%	14.62M
REGENERON PHARMACEUTICALS, INC.	-1.48%	-5.59%	+39.55%	-5.42%	78.04B
MODERNA, INC.	+5.38%	-1.09%	+512.38%	+32.58%	57.48B
CSL LIMITED	+2.53%	-1.10%	-16.24%	-35.83%	57.4B
SAMSUNG BIOLOGICS CO.,LTD.	-0.56%	-2.21%	-11.34%	+27.29%	48.81B
UCB	+1.93%	-2.37%	-0.87%	+151.53%	45.5B
BIOGEN INC.	+0.80%	-1.67%	+49.90%	-15.15%	32.08B
INCYTE CORPORATION	-1.47%	-4.17%	+46.17%	+92.50%	24.62B
INNOVENT BIOLOGICS, INC.	+2.24%	-5.53%	+0.10%	+153.51%	20.77B
SWEDISH ORPHAN BIOVITRUM AB	-0.09%	-3.61%	+62.49%	+99.45%	15.75B
Average	+0.74%	-4.56%	+64.90%	+43.60%	38.04B
Weighted average by Cap.	+1.14%	-3.71%	+91.30%	+37.23%

	2026 *	2027 *
Net sales	6.6M 7.66M 6.25M 5.66M 10.63M 732M 10.68M 74.22M 28.54M 372M 28.77M 28.14M 1.18B	8M 9.29M 7.57M 6.87M 12.88M 887M 12.95M 89.97M 34.6M 451M 34.87M 34.11M 1.43B
Net income	-6.7M -7.78M -6.34M -5.75M -10.79M -743M -10.84M -75.35M -28.97M -378M -29.2M -28.56M -1.19B	-6.2M -7.2M -5.87M -5.32M -9.98M -687M -10.03M -69.72M -26.81M -350M -27.02M -26.43M -1.11B
Net Debt	23.1M 26.81M 21.87M 19.83M 37.19M 2.56B 37.38M 260M 99.9M 1.3B 101M 98.48M 4.12B	29.2M 33.89M 27.65M 25.06M 47.02M 3.24B 47.25M 328M 126M 1.65B 127M 124M 5.21B